Company Overview - Alumis Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation targeted therapies for immune-mediated diseases [5] - The company is leveraging a proprietary data analytics platform and precision approach to develop its pipeline of therapies [5] Public Offering Announcement - Alumis announced plans to commence an underwritten public offering of $175.0 million of its common stock, with an additional option for underwriters to purchase up to $26.25 million of shares [1] - The offering is subject to market conditions and there is no assurance regarding its completion or terms [1] Management of the Offering - Morgan Stanley, Leerink Partners, Cantor, and Wells Fargo Securities are acting as joint book-running managers for the proposed offering [2] Regulatory Compliance - The offering is being made pursuant to a shelf registration statement on Form S-3, which was previously filed and declared effective by the SEC on August 19, 2025 [3] - A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC and will be available for free on the SEC's website [3]
Alumis Announces Proposed Public Offering of Common Stock